54 related articles for article (PubMed ID: 33773750)
1. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
[TBL] [Abstract][Full Text] [Related]
2. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Kött J; Zimmermann N; Zell T; Rünger A; Heidrich I; Geidel G; Smit DJ; Hansen I; Abeck F; Schadendorf D; Eggermont A; Puig S; Hauschild A; Gebhardt C
Eur J Cancer; 2024 May; 202():113989. PubMed ID: 38518535
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
[TBL] [Abstract][Full Text] [Related]
6. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
[TBL] [Abstract][Full Text] [Related]
7. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies.
Dhillon S; Duarte-Bateman D; Fowler G; Hagstrom MNE; Lampley N; Olivares S; Fumero-Velázquez MS; Vu K; Wayne JD; Gastman BR; Vetto J; Gerami P
Arch Dermatol Res; 2023 Oct; 315(8):2295-2302. PubMed ID: 36977840
[TBL] [Abstract][Full Text] [Related]
8. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration.
Bailey CN; Martin BJ; Petkov VI; Schussler NC; Stevens JL; Bentler S; Cress RD; Doherty JA; Durbin EB; Gomez SL; Gonsalves L; Hernandez BY; Liu L; Morawski BM; Schymura MJ; Schwartz SM; Ward KC; Wiggins C; Wu XC; Goldberg MS; Siegel JJ; Cook RW; Covington KR; Kurley SJ
JCO Precis Oncol; 2023 Jun; 7():e2300044. PubMed ID: 37384864
[TBL] [Abstract][Full Text] [Related]
9. The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma.
Podlipnik S; Martin BJ; Morgan-Linnell SK; Bailey CN; Siegel JJ; Petkov VI; Puig S
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254778
[TBL] [Abstract][Full Text] [Related]
10. Primary dermal melanoma: a unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma: a clinical, histologic, and gene expression-profiling study.
Sidiropoulos M; Obregon R; Cooper C; Sholl LM; Guitart J; Gerami P
J Am Acad Dermatol; 2014 Dec; 71(6):1083-92. PubMed ID: 25262174
[TBL] [Abstract][Full Text] [Related]
11. Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts.
Fastner S; Shen N; Hartman RI; Chu EY; Kim CC; Kirkwood JM; Grossman D
Cancer Med; 2023 Dec; 12(24):22103-22108. PubMed ID: 38098216
[TBL] [Abstract][Full Text] [Related]
12. Relationship of Histopathologic Parameters and Gene Expression Profiling in Malignant Melanoma.
Strahan AG; Švagelj I; Jukic D
Am J Clin Dermatol; 2024 Jan; 25(1):119-126. PubMed ID: 37667131
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of the 31-Gene Expression Profile Test on the Management of Cutaneous Melanoma by Nurse Practitioners and Physician Assistants.
Block R; Patterson D; Siegel JJ; Martin B; Quick AP; Hunt J
J Adv Pract Oncol; 2023 Nov; 14(7):586-596. PubMed ID: 38196667
[TBL] [Abstract][Full Text] [Related]
14. Risk prediction in cutaneous melanoma patients from their clinico-pathological features: superiority of clinical data over gene expression data.
Arora C; Kaur D; Lathwal A; Raghava GPS
Heliyon; 2020 Aug; 6(8):e04811. PubMed ID: 32913910
[TBL] [Abstract][Full Text] [Related]
15. Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-Analysis.
Ahmadi O; Das M; Hajarizadeh B; Mathy JA
Ann Surg Oncol; 2021 Oct; 28(11):6168-6176. PubMed ID: 33782802
[TBL] [Abstract][Full Text] [Related]
16. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
18. Impact of a see-and-treat melanoma clinic on patient experience.
Ip KH; Agnew K; Cranshaw I; Ng A; Chandran A
J Dermatolog Treat; 2022 Jun; 33(4):2021-2023. PubMed ID: 33792467
[TBL] [Abstract][Full Text] [Related]
19. The association between citrus consumption and melanoma risk in the UK Biobank.
Marley AR; Li M; Champion VL; Song Y; Han J; Li X
Br J Dermatol; 2021 Aug; 185(2):353-362. PubMed ID: 33782946
[TBL] [Abstract][Full Text] [Related]
20. Position statement of the EADV Melanoma Task Force on recommendations for the management of cutaneous melanoma patients during COVID-19.
Arenbergerova M; Lallas A; Nagore E; Rudnicka L; Forsea AM; Pasek M; Meier F; Peris K; Olah J; Posch C
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e427-e428. PubMed ID: 33780557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
